Silexion Therapeutics Warrant
SLXNW
26 hedge funds and large institutions have $91.7K invested in Silexion Therapeutics Warrant in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
23.55% more ownership
Funds ownership: 0% → 23.55% (+24%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
14% less capital invested
Capital invested by funds: $106K → $91.7K (-$14.4K)
16% less funds holding
Funds holding: 31 → 26 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$945 |
| 2 |
Walleye Trading
New York
|
+$844 |
| 3 |
Goldman Sachs
New York
|
+$570 |
| 4 |
CS
Clear Street
New York
|
+$338 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCIA
Gabelli & Co Investment Advisers
Rye,
New York
|
-$1.21K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1K |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
-$967 |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$698 |
| 5 |
Walleye Capital
New York
|
-$666 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of America
Charlotte,
North Carolina
| $9 | +$7 | +165 | +165% |
|
|
GCIA
27
Gabelli & Co Investment Advisers
Rye,
New York
| – | -$1.21K | -38,150 | Closed |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$1.1K | -34,577 | Closed |
|
|
GF
29
Gabelli Funds
Rye,
New York
| – | -$967 | -30,496 | Closed |
|
|
30
Walleye Capital
New York
| – | -$666 | -21,000 | Closed |
|
|
BOCH
31
Blue Owl Capital Holdings
New York
| – | -$396 | -12,500 | Closed |
|
|
AA
32
AQR Arbitrage
Greenwich,
Connecticut
| – | -$390 | -12,313 | Closed |
|
SLXNW Hedge Fund Activity: Q4 2024 in Review
26 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q4 2024, worth a combined $91.7K — down 14% from $106K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SLXNW and 1 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was GTS Securities, opening a new position worth an estimated $945. The largest seller was Gabelli & Co Investment Advisers, exiting entirely with an estimated $1.21K sold.
- 26 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q4 2024, down from 31 in Q3 2024.
- Funds reported $91.7K of Silexion Therapeutics Warrant stock for Q4 2024, down 14% quarter-over-quarter.
- 1 fund opened new Silexion Therapeutics Warrant positions in Q4 2024 and 6 closed out, a net change of -5 holders.
- The largest Silexion Therapeutics Warrant buyer in Q4 2024 was GTS Securities, an estimated $945 added.
- The largest Silexion Therapeutics Warrant seller in Q4 2024 was Gabelli & Co Investment Advisers, an estimated $1.21K sold.
Based on aggregated 13F filings for Q4 2024.